Asia Pacific Cell Therapy Bioprocessing Market is expected to reach US$ 5,872.3 Million by 2028


PRESS RELEASE BY The Insight Partners 29 Aug 2021

Share this press on


Bioreactor Segment has the Largest Share of Technology in the Asia Pacific Cell Therapy Bioprocessing Market during 2021–2028

According to The Insight Partners market research study on “Asia Pacific Cell Therapy Bioprocessing Market to 2028 – COVID-19 Impact and Regional Analysis and Forecast by Technology, Cell Type, Indication, and End User” is expected to reach US$ 5,872.3 million by 2028 from US$ 2,347.0 million in 2021. The market is estimated to grow at a CAGR of 14.0% from 2021 to 2028. The report provides trends prevailing in the Asia Pacific Cell therapy bioprocessing market along with the drivers and restraints pertaining to the market growth. The growth of this market is estimated to grow owing to key driving factors such as the increasing investments for cell and gene therapy manufacturing, and growing approvals for cell therapies are the key factors driving the market growth. However, the market is expected experiencing slow growth during the forecast period owing to the challenges such as high cost of product, regulatory challenges, and logistics challenges.

COVID-19 has created an extraordinary emergency that is particularly affecting the supply chain. The supply chain disruptions, along with the enormous demand for effective therapies for the treatment of COVID 19 has put healthcare research industry in critical situation in Asia Pacific region. However, many of the market players now realized the importance of cell therapy in treatment of COVID 19 which is expected to raise demand for cell therapy bioprocessing during forecast period. China's short-term responses was similar to those of the United States and Europe. Most transactions remain largely unaffected, awareness of the need for better supply chain control. There have been no major supply changes, such as switching to domestic Chinese bioprocessing providers rather than Western bioprocessing providers. Indeed, significant public investments in pandemic-related vaccines and therapeutics are anticipated. The hope has also grown that trade imbalances between the United States and China will be easily bridged in favor of domestic health policy. The government is also attempting to implement anticipated economic reforms in order to make them more market driven. The pandemic is likely to be a catalyst in the spread of such trends.

The market for cell therapy bioprocessing market is segmented into technology, cell type, indication, and end user. Based on technology, in 2020, the bioreactor segment accounted for the cell therapy bioprocessing market's most significant market share. The segment's growth is expected due to its utilization for making cells and scaling up the volume for cellular products. Bioreactors are the primary equipment required during the cell therapy bioprocessing thus are expected to continue their dominancy during the forecast period. However, the genome-editing technology segment is expected to grow at the fastest CAGR. Genome editing technology is widely used for targeting and designing the cellular and genes for cell therapies.

Fresenius Kabi Ag., Asahi Kasei Corporation, Sartorius Ag, Merck Kgaa, Thermo Fisher Scientific Inc., Corning Incorporated, Cytiva (Ge Healthcare), Lonza, Repligen, and Catalent Inc are among the leading companies in the Asia Pacific cell therapy bioprocessing market. The companies are focused on adopting organic growth strategies such as product launches and expansions to sustain their position in the dynamic market. For instance, in January 2021, Sartorius Partners with RoosterBio. The partnership seeks to drive the scale-up of hMSC production for regenerative medicine by exploiting both companies' best-in-class solutions to dramatically minimise process development efforts, industrialise the supply chain, and accelerate the growth and commercialization of game-changing cell-based regenerative cures. 

The market for cell therapy bioprocessing market is segmented into technology, cell type, indication, and end user. Based on technology, the Cell therapy bioprocessing market is segmented into bioreactor, lyophilization, electrospinning, control flow centrifugation, ultrasonic lysis, genome editing technology, cell immortalization technology, and viral vector technology. Based on cell type, the cell therapy bioprocessing market is segmented into stem cell, immune cell, human embryonic stem cell, pluripotent stem cell, and hematopoietic stem cells. Based on indication, the cell therapy bioprocessing market is segmented into cardiovascular disease (cvd), oncology, wound healing, orthopaedic, and others. Based on end user, the cell therapy bioprocessing market is segmented into hospitals and clinics, diagnostic centres, regenerative medicine centres, and academic and research institute. Geographically, the cell therapy bioprocessing market is segmented into Asia Pacific (China, Japan, India, South Korea, Australia, Rest of Asia Pacific).

Contact Us
 
Phone: +1-646-491-9876
Email Id: sales@theinsightpartners.com               

Download Free PDF Brochure